Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Falls 4.3% – Should You Sell?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) fell 4.3% during mid-day trading on Tuesday. The company traded as low as $4.74 and last traded at $4.5750. Approximately 14,149,966 shares traded hands during trading, a decline of 24% from the average session volume of 18,554,494 shares. The stock had previously closed at $4.78.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on RXRX. Morgan Stanley set a $5.30 price target on Recursion Pharmaceuticals in a research report on Monday, August 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Finally, Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.06.

Recursion Pharmaceuticals Stock Down 4.3%

The company’s 50 day moving average is $3.47 and its 200 day moving average is $3.36. The company has a market cap of $2.45 billion, a PE ratio of -4.39 and a beta of 1.04. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The company had revenue of $7.67 million during the quarter, compared to the consensus estimate of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same quarter in the prior year, the company earned ($0.41) earnings per share. As a group, analysts predict that Recursion Pharmaceuticals, Inc. will post -0.94 earnings per share for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, CEO Najat Khan sold 22,408 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total transaction of $78,876.16. Following the transaction, the chief executive officer owned 2,072,890 shares of the company’s stock, valued at approximately $7,296,572.80. This represents a 1.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $3.34, for a total value of $100,200.00. Following the completion of the sale, the director owned 6,158,287 shares of the company’s stock, valued at $20,568,678.58. The trade was a 0.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 82,408 shares of company stock valued at $276,576 over the last quarter. Company insiders own 6.65% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Norges Bank acquired a new position in Recursion Pharmaceuticals during the fourth quarter valued at $23,473,000. Renaissance Technologies LLC acquired a new position in Recursion Pharmaceuticals during the first quarter worth $7,370,000. Hsbc Holdings PLC boosted its holdings in Recursion Pharmaceuticals by 537.3% in the 4th quarter. Hsbc Holdings PLC now owns 818,316 shares of the company’s stock worth $3,367,000 after buying an additional 689,903 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Recursion Pharmaceuticals by 18.2% in the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock worth $7,665,000 after buying an additional 384,486 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in shares of Recursion Pharmaceuticals by 15.2% in the 1st quarter. First Trust Advisors LP now owns 2,610,726 shares of the company’s stock worth $8,015,000 after acquiring an additional 344,035 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.